Treatment Updates

Cases in Point: Risk Factors, Surveillance Strategies, and Treatment Options for Hepatocellular Carcinoma

CCO Slideset

• Cases in Point: Risk Factors, Surveillance Strategies, and Treatment Options for Hepatocellular Carcinoma

HBV Providers’ Choice in Prime Time: Addressing Issues of Patient Populations, Resistance, Individualized Treatment, Management, and Efficacy

Interactive Virtual Presentations

• HBV Patient Populations: Treating HBV in the Setting of Pregnancy (coming soon)
• HBV Patient Populations: Treating HBV in the Setting of Pregnancy
• Efficacy, Resistance, and Durability (coming soon)
• Efficacy, Resistance, and Durability
• Management of Suboptimal Response (coming soon)
• Management of Suboptimal Response

Management of Depression and HCV: Novel Data, Best Practices, and Case Challenges

Modules

• Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin
• Answering the Questions: Depression Related to HCV and Its Treatment

Slideset Modules

• Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin
• Clinical Data and Best Practices for Managing Depression in HCV-Infected Patients Treated With Peginterferon and Ribavirin
• Answering the Questions: Depression Related to HCV and Its Treatment
• Answering the Questions: Depression Related to HCV and Its Treatment

Interactive Case Challenges

• Management of a 43 Year-Old HCV-Infected, Treatment-Naive Female With a History of Major Depression
• Management of a Patient Who Develops Psychiatric Adverse Events While Receiving Peginterferon Therapy for HCV
• Management of Emergent Depression and Suicidal Ideation During HCV Therapy

Expert Viewpoints

New Options for HCV Nonresponders: Navigating Emerging Data and Best Practices for Treatment-Experienced Patients

Part 1 - Management of Previous HCV Treatment Nonresponders

Virtual Presentation

• Management of HCV Nonresponders
• Management of HCV Nonresponders

Interactive Case Challenge

• Treatment of a Genotype 1a Patient Not Achieving Full Virologic Suppression With Peginterferon/Ribavirin at 24 Weeks

Part 2 - Optimizing and Individualizing HCV Retreatment

Virtual Presentation

• Maintaining Patients on Treatment: Optimizing and Individualizing Retreatment for Success
• Maintaining Patients on Treatment: Optimizing and Individualizing Retreatment for Success

Interactive Case Challenge

• Optimizing Treatment Success of a Second HCV Regimen in a Patient With Unsuccessful Initial Treatment With Peginterferon alfa-2a and Ribavirin

HBV Core Curriculum 2008

Virtual Presentations

• Epidemiology and Natural History of HBV
• Epidemiology and Natural History of HBV
• Treatment and Management of Chronic HBV Infection
• Treatment and Management of Chronic HBV Infection

HBV Patient Monitoring Worksheets

• Worksheets

Interactive Tool

• HBV Screening, Evaluation, and Monitoring
  an Interactive Decision Support Tool

HBV Election 2008: Meet the Clinical Candidates

Virtual Presentation

• New Clinical Candidates for HBV
• New Clinical Candidates for HBV

On-Treatment Management Strategies for Chronic Hepatitis B

Interactive Case Challenge

• On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapy

Virtual Presentation

• Active Management of Oral Nucleos(t)ide Analogue Therapy for Hepatitis B
• Active Management of Oral Nucleos(t)ide Analogue Therapy for Hepatitis B

Virologic Tools for Monitoring Patients With Chronic Hepatitis B

Module

• Virologic Monitoring in Hepatitis B: Tools for Determining Treatment Candidacy and Response

Interactive Case Challenge

• Management of a 52-Year-Old HBeAg-Positive, Treatment-Naive Female Seeking Hepatitis B Therapy

Interactive Tool

• HBV DNA Monitoring for Oral Agents

Drug Resistance in Chronic Hepatitis B: From Definitions to Management Strategies

Modules

• Defining HBV Resistance: Interpreting and Applying Clinical Data

Virtual Presentations

• A Case-Based Approach to Managing Resistance in Chronic HBV Infection

CCO Slideset

• A Case-Based Approach to Managing Resistance in Chronic HBV Infection

Case Debates With the Experts: Applying the Updated Practice Guidelines to the Management of Hepatitis B

Interactive Case Challenges

• Management of a Treatment-Naive, HBeAg-Positive, Asian American Patient
• Management of an HBeAg-Positive Patient on Active Antiviral Therapy Who Has Failed to Achieve a Primary Response
• Management of an HBeAg-Negative Patient With Lamivudine Resistance

CCO Slidesets

• Debate: Nucleos(t)ide Analogues vs Peginterferon in Treatment-Naive HBeAg-Positive Patients
• Debate: What Is the Best Rescue Strategy for the Management of Primary Nonresponse: Switch or Add?
• Debate: What Is the Optimal Management Strategy for Lamivudine Resistance in HBeAg-Negative Patients?

New Management Strategies for HCV Nonresponders and Relapsers

Module

• Understanding HCV Nonresponse and Identifying Candidates for Retreatment

Interactive Case Challenge

• Retreatment of a Patient With Chronic HCV Infection and Previous Treatment Failure

Slideset Module

• New Management Strategies for HCV Nonresponders and Relapsers
• New Management Strategies for HCV Nonresponders and Relapsers

On-Demand Teleconference

• Download Audio from Teleconference

The Future of HCV: Small Molecules in Development for Chronic Hepatitis C

Modules

• Clinical Need and Therapeutic Targets for New HCV Agents
• Investigational Small Molecule Agents for the Treatment of Chronic Hepatitis C
• Current Issues in the Development and Clinical Role of Novel Agents for Chronic Hepatitis C

Print-on-Demand Monograph

• Print on Demand

Depression Associated With HCV Infection and Its Therapy: Impact on Patient Management

Modules

• Risk and Mechanisms of Depression in HCV
• Depression and Suicidal Risk Associated With HCV Treatment
• Strategies for Preventing, Diagnosing, and Managing Depression in Patients Receiving HCV Therapy

CCO Slidesets

• Risk and Mechanisms of Depression in HCV
• Depression and Suicidal Risk Associated With HCV Treatment
• Strategies for Preventing, Diagnosing, and Managing Depression in Patients Receiving HCV Therapy

HCV and Methadone Maintenance

CME-Certified Slidesets

• HCV Epidemiology and Impact on Intravenous Drug User Risk and Screening
• HCV Epidemiology and Impact on Intravenous Drug User Risk and Screening
• HCV Diagnosis and Natural History
• HCV Diagnosis and Natural History
• Management of Treatment-Naive Chronic HCV Patients
• Management of Treatment-Naive Chronic HCV Patients
• Current Management of Treatment-Experienced Chronic HCV Patients
• Current Management of Treatment-Experienced Chronic HCV Patients
• Managing Adverse Effects of the Treatment of Chronic HCV
• Managing Adverse Effects of the Treatment of Chronic HCV

HCV Treatment Pocket Guides

• Pocket Guides

HCV Patient Monitoring Worksheets

• Worksheets

Focus on the Virus: A New Paradigm for the Management and Treatment of HBV

Modules

• Understanding HBV: Viral Load and Disease Progression
• New Measures of Treatment Success: Recent Data on Potency and On-Treatment Response
• Management of Resistance: Implications for Treatment Choice

Interactive Case Challenges

• Management of an HBeAg-Negative Patient With Cirrhosis and Elevated Alanine Aminotransferase
• Management of an HBeAg-Positive Patient With Borderline-Normal ALT and Family History of Liver Cancer

CCO Slidesets

• Viral Load and Disease Progression
• New Measures of Treatment Success: Recent Data on Potency and On-Treatment Response
• Management of Resistance: Implications for Treatment Choices

Diagnosing and Treating Chronic Hepatitis C: Management Tools for NPs and PAs

Virtual Presentations

• Managing Therapeutic Challenges in Hepatitis C
• CCO Slideset – Managing Therapeutic Challenges in Hepatitis C
• HCV On-Treatment Virologic Monitoring: Impact on Treatment Decisions
• CCO Slideset – HCV On-Treatment Virologic Monitoring: Impact on Treatment Decisions

Interactive Case Challenges

• Management of a 54-Year-Old Man with HCV, Diabetes, and a History of Depression
• Management of an HCV-Infected Patient Using Virologic Responses to Therapy

Interactive Algorithm Tool

• HCV Treatment Guidelines Algorithm
  An Interactive Decision Support Tool

Practical Strategies for the Management of Patients With Drug-Resistant HBV

Modules

• Causes and Management of Drug-Resistant HBV

CCO Slidesets

• Causes and Management of Drug-Resistant HBV Infection

HCV Core Curriculum

Virtual Presentations

• Hepatitis C: Epidemiology, Diagnosis and Treatment
• CCO Slideset – Hepatitis C: Epidemiology, Diagnosis and Treatment

HBV Core Curriculum

Virtual Presentations

• Epidemiology, Prevention and Treatment of Hepatitis B
• CCO Slideset – Epidemiology, Prevention and Treatment of Hepatitis B
• Current Treatment Options for Hepatitis B
• CCO Slideset – Current Treatment Options for Hepatitis B

Clinical Strategies for Preventing and Managing Resistance to Anti-HBV Agents

Modules

• Assessing HBV Virologic Markers
• Role of HBV DNA in Patient Management
• Definitions of HBV Treatment Failure and Resistance
• Natural History of Hepatitis B Virus Infection
• Natural History of Chronic HBV Infection in Patients Receiving Anti-HBV Therapy
• Outcomes After HBV Treatment Failure Due to Resistance
• Contending With HBV Resistance: Lessons Learned From HIV Resistance and Its Management
• Translating Lessons Learned with HIV Resistance Assays Into Tools for Hepatitis B Virus Resistance Treatment
• Summary of Mutations Associated With Resistance to HBV Drugs
• Tools for the Assessment of HBV Resistance in Clinical Practice

A New Era for Treatment: Advanced Issues in the Long-Term Management of Chronic HBV

Modules

• Goals and Challenges in the Treatment of Hepatitis B
• Clinical Data on Long-Term Treatment of Hepatitis B
• Strategies for Managing Resistance to Nucleoside/Nucleotide Analogues

Interactive Case Challenges

• A 42-year-old man with lamivudine-resistant HBeAg-negative chronic hepatitis B infection
• A 35-year-old Asian man with previously untreated HBeAg-positive chronic hepatitis B infection

CCO Slidesets

• Goals and Challenges in the Treatment of Hepatitis B
• Clinical Data on Long-Term Treatment of Hepatitis B
• Strategies for Managing Resistance to Nucleoside/Nucleotide Analogues

Doc Eye for the Hep Guy: Management of HCV Treatment-Experienced Patients

On-Demand Video Conference

• Doc Eye for the Hep Guy: Management HCV Treatment–Experienced Patients
• CCO Slideset – Doc Eye for the Hep Guy: Management of HCV Treatment–Experienced Patients

CCO Slidesets

• Management of the HCV Therapy-Experienced Patient
• Treatment of HCV in Special Populations
• Management of Hematologic Side Effects to Optimize Response Rates to HCV Therapy

Modules

• Management of the HCV Therapy-Experienced Patient
• Treatment of HCV in Special Populations
• Management of Hematologic Side Effects to Optimize Response Rates to HCV Therapy
• Entire Program in a Single Module: Doc Eye for the Hep Guy

Altering the Progression of Chronic Hepatitis B: Evidence and Urgency

Modules

• Why Treat Hepatitis B Now? The Clinical View
• Why Should We Treat Hepatitis B Now? The Economic View
• What Can We Expect in the Future?

Interactive Case Challenges

• A 47-Year-Old Italian-American Man With Cirrhotic Hepatitis B
• A 28-Year-Old Physician With HBeAg-Positive Disease
• A 43-Year-Old Man With Asymptomatic HBeAg-Negative Disease

Corresponding PowerPoints for Each Module

• Why Treat Hepatitis B Now? The Clinical View
• Why Should We Treat Hepatitis B Now? The Economic View
• What Can We Expect In the Future?

The Great Debate: Treatment of HBV and the Impact on Transplantation

Modules

• Update on Treatment Guidelines for Chronic Hepatitis B in the Transplant Setting
• What is the Optimal Duration of Antiviral Therapy in Patients with Hepatitis B-Related Cirrhosis?
• Management of HBV Reinfection Following Liver Transplantation

Interactive Case Challenges

• A Middle-Aged Man with Chronic Hepatitis B Awaiting Transplantation
• A 43-Year-Old Liver Transplant Recipient with De Novo Hepatitis B Arising after Transplantation
• A 56-Year-Old Liver Transplant Recipient with Recurrent Hepatitis B

CCO Slidesets

• Management of HBV Reinfection After Liver Transplantation (pdf format)
• Update on Treatment of Chronic HBV in the Liver Transplant Setting
• The Optimal Duration of Treatment for Chronic HBV Cirrhosis: Until Endpoints Are Reached
• The Optimal Duration of Treatment for Chronic HBV Cirrhosis: Indefinite

An Update on Ribavirin Analogues: Meeting the Challenge of Anemia in Hepatitis C Treatment

Modules

• Treating HCV-infected Patients at High Risk of Anemia
• Ribavirin Analogues and Ribavirin-like Molecules: New Directions in Antiviral Therapy

Interactive Case Challenges

• Management of Chronic Hepatitis C in a Man with HIV Coinfection
• Management of a Treatment-Naive Man with HCV Genotype 1 and Advanced Fibrosis

Corresponding PowerPoints for each Module

• Treating HCV-infected Patients at High Risk of Anemia
• Ribavirin Analogues and Ribavirin-like Molecules: New Directions in Antiviral Therapy

Overcoming Clinical Challenges in the Management of Hepatitis C

Modules

• Special Populations: Managing HCV in African-Americans and Liver Transplantation Patients
• Management of HCV-Associated Fibrosis
• Treatment Decisions: Nonresponders and Relapsers After HCV Treatment

Hepatitis C: Treating the Virus, Healing the Patient

Modules

• Challenges in Treating Special Populations: Nonresponders, Acute Infection, African Americans, and HIV Coinfected Patients
• Management of Hepatitis C and Managing Side Effects: A Team-Based Approach to Treatment

CCO Slidesets

• Brown - Management of Hepatitis C
• Gross - Clinical Treatment Decisions: Nonresponders and Acute Infection

Evidence-Based Management of Hepatitis C: A Clinician's Guide to Pegylated Interferons

Modules

• Evidence-Based Management of Hepatitis C: A Clinician's Guide to Pegylated Interferons

Peginterferons in HCV: Structural Differences with Pharmacokinetic, Virological, and Clinical Implications

Modules

• Peginterferons in HCV: Structural Differences with Pharmacokinetic, Virological and Clinical Implications